Sunday, January 18, 2009

Nycomed gets rights to develop & market EffRx's osteoporosis drug alendronate

Nycomed and EffRx announced a licensing agreement on EffRx' drug EX101 (effervescent alendronate) for the treatment of osteoporosis.

The details can be read here.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)